- Annexon Announces Pricing of $125 Million Underwritten Public Offering
- Annexon Announces Proposed Public Offering of Common Stock
- Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
- Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
- Annexon Biosciences to Present at the Bank of America Health Care Conference
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
- Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
- Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
On Friday, Annexon Inc (ANNX:NSQ) closed at 5.74, -31.67% below its 52-week high of 8.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.78 |
---|---|
High | 5.82 |
Low | 5.32 |
Bid | -- |
Offer | -- |
Previous close | 5.74 |
Average volume | 8.49m |
---|---|
Shares outstanding | 92.41m |
Free float | 84.60m |
P/E (TTM) | -- |
Market cap | 627.48m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼